Stifel Lowers Price Target on Outset Medical, Inc. (OM) to $8, Maintains Buy Rating

We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. 

On January 7, Stifel analyst Rick Wise lowered the price target on Outset Medical, Inc. (NASDAQ:OM) to $8 from $14 while maintaining a Buy rating on the shares. The adjustment reflects near-term pressures in MedTech following 2025, though the firm remains constructive on the sector overall for 2026.

Outset Medical, Inc. (NASDAQ:OM) continues to demonstrate steady growth in its dialysis solutions business. In Q3 2025, the company reported revenue of $29.4 million, up 3% year-over-year, and raised its 2025 revenue guidance to a range of $115 million to $120 million. Tablo console sales increased 8% in the quarter, driven by growing hospital demand and an expanding sales pipeline, with opportunities increasing in size by more than 20%. These trends underscore Outset’s ability to capture market share and support long-term growth.

Founded in 2003 and headquartered in San Jose, California, Outset Medical, Inc. (NASDAQ:OM) is focused on transforming dialysis, which is one of healthcare’s largest and most expensive segments, through innovative technology, research, and North American manufacturing operations.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.